AFM13
AFM13-203
Phase 2 small_molecule terminated
Quick answer
AFM13 for Relapsed or Refractory Hodgkin Lymphoma is a Phase 2 program (small_molecule) at Artiva Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Artiva Biotherapeutics
- Indication
- Relapsed or Refractory Hodgkin Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated